Back to News
Market Impact: 0.15
SeaStar Medical Congratulates H. David Humes, M.D., on Receiving the University of Michigan 2026 Distinguished University Innovator of the Year for Development of the SCD Therapy
Source: GlobeNewswire
Healthcare & BiotechProduct LaunchesTechnology & Innovation
Dr. Humes received a prestigious honor for pioneering the Selective Cytopheretic Device (SCD) therapy. SeaStar Medical has commercialized the therapy as QUELIMMUNE for critically ill pediatric patients with acute kidney injury, highlighting external recognition of its medical-device innovation.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.35
Ticker Sentiment
ICU0.75
More News
- Key AI chip index just broke its long-term trendline. What history says happens next
- Banks, investors grow wary of AI debt, spooked by market selloff
- Eli Lilly’s Foundayo obesity pill eases sleep apnea in late-stage trial, paving way for approval
- Moody’s and S&P downgrade Akamai on debt-fueled AI infrastructure buildout
- Why is Nvidia’s Jensen Huang at the centre of a US-China spy scandal?
- CoreWeave confronts 'doom cycle' narrative as neocloud credit risk overshadows growth